½ÃÀ庸°í¼­
»óǰÄÚµå
1279886

¼¼°èÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : ÄÄÆ÷³ÍÆ®º°, ¸ð´Þ¸®Æ¼º°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®(2023-2030³â)

Global Medical Hyperspectral Imaging Market Size study & Forecast, by Component by Modality, by Application, by End User and Regional Analysis, 2023-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀåÀº 2022³â ¾à 15¾ï 8,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2023-2030³â¿¡´Â 13.1% ÀÌ»óÀÇ °ÇÀüÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÇ·á¿ë Ãʺб¤ À̹Ì¡Àº ÀÇ·á ºÐ¾ß¿¡¼­ »ýü Á¶Á÷ÀÇ ½ºÆåÆ®·³ Ư¼º¿¡ ´ëÇÑ »ó¼¼ÇÑ Á¤º¸¸¦ ȹµæÇÏ°í ºÐ¼®Çϱâ À§ÇØ »ç¿ëµÇ´Â Àü¹® À̹Ì¡ ±â¼úÀÔ´Ï´Ù. ±âÁ¸ÀÇ À̹Ì¡°ú ºÐ±¤ÇÐ ¿ø¸®¸¦ °áÇÕÇÏ¿© Á¶Á÷ÀÇ È­ÇÐÀû ¹× ±¸Á¶Àû ±¸¼º¿¡ ´ëÇÑ Ç³ºÎÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ´Â ¹è°æ¿¡´Â ¾Ï Áõ°¡¿Í ÀÇ·áÀû Ȱ¿ëÀ» À§ÇÑ ¿¬±¸ Áõ°¡ µîÀÇ ¿äÀÎÀÌ ÀÖ½À´Ï´Ù.

±¹Á¦¾Ï¿¬±¸¼Ò(IARC)ÀÇ ÃßÁ¤¿¡ µû¸£¸é ¼¼°è ¾Ï ¹ß»ý °Ç¼ö´Â 2021³â 190¸¸ °Ç¿¡¼­ 2020³â±îÁö 2,750¸¸ °ÇÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ¿©·¯ ¿¬±¸ °á°ú´Â ¾Ï Áø´Ü¿¡¼­ Ãʺб¤ À̹Ì¡ÀÇ È¿°ú¸¦ Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2022³â Springer Nature¿¡ °ÔÀçµÈ ¿¬±¸ ³í¹®¿¡ µû¸£¸é Ãʺб¤ À̹Ì¡Àº ¼ö¼ú ÈÄ Á¦°ÅÇÑ À¯¹æ Á¶Á÷¿¡¼­ À¯¹æ¾ÏÀ» ¾à 84%ÀÇ ¹Î°¨µµ·Î Á¤È®ÇÏ°Ô Áø´ÜÇÒ ¼ö ÀÖ´Ù°í ÇÕ´Ï´Ù. ¶ÇÇÑ ÀÇ·á¿ë ÇÏÀÌÆÛ½ºÆåÆ®·³ ¿µ»óÀ¸·Î ¸î ºÐ ¾È¿¡ Á¶Á÷À» ºÐ¼®ÇÏ¿© ÀýÁ¦ ºÎÀ§ °¡ÀåÀÚ¸®¿¡ Á¾¾ç ¼¼Æ÷°¡ ³²¾Æ ÀÖ´ÂÁö ¿©ºÎ¸¦ ÆÇ´ÜÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹Ãø ±â°£ Áß ½ÃÀåÀÌ È®´ëµÇ´Â ÁÖ¿ä ÀÌÀ¯ Áß Çϳª´Â ÀÌ ±â¼úÀÌ ¾ÏÀ» ŽÁöÇÏ´Â µ¥ À¯¿ëÇϰí Á¤È®Çϱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ Á¦¾à ȸ»çÀÇ ¾à¹° °Ë»ç¿¡ ´ëÇÑ ÁöÃâ Áõ°¡¿Í ±â¼ú ¹ßÀüÀº ½ÃÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ÀÇ ³ôÀº ºñ¿ëÀº 2023-2030³âÀÇ ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» ÀúÇØÇϰí ÀÖ½À´Ï´Ù.

¼¼°èÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÇ´Â ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÔ´Ï´Ù. ºÏ¹Ì´Â ¾Ï À¯º´·ü Áõ°¡, Ȱ¹ßÇÑ R&D Ȱµ¿ ¹× ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¸Àç·Î ÀÎÇØ 2022³â ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¾Ï ¹ßº´·ü Áõ°¡, Á¦Ç° °³¹ßÀ» À§ÇÑ °øµ¿ ¿¬±¸ ¼ö Áõ°¡, ÁÖ¿ä ±â¾÷ÀÇ Áö¿ªÀû È®Àå, Á¤ºÎ ±â°ü ¹× ºñ¿µ¸® ´Üü ½ÃÀå ÁøÀÔ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß Å« ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ¿¬±¸ÀÇ ¸ñÀûÀº ÃÖ±Ù ¼ö³â°£ ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ ÆÄ¾ÇÇϰí ÇâÈÄ ¼ö³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â Á¶»ç ´ë»ó ±¹°¡ÀÇ »ê¾÷ÀÇ ÁúÀû, ¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦¿Í °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ °æÀï ȯ°æ°ú ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀå¿¡¼­ÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇԵ˴ϴÙ.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ½º³À¼ô
  • ¼¼°è ½ÃÀ塤ºÎ¹®º° ½ÃÀå ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
    • ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå : Áö¿ªº°, 2020-2030³â
    • ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå, ÄÄÆ÷³ÍÆ®º°, 2020-2030³â
    • ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå, ¸ð´Þ¸®Æ¼º°, 2020-2030³â
    • ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå, ¿ëµµº°, 2020-2030³â
    • ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2020-2030³â
  • ÁÖ¿ä µ¿Çâ
  • Á¶»ç ¹æ¹ý
  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç

Á¦2Àå ¼¼°èÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • Á¶»ç ¸ñÀû
  • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
    • »ê¾÷ÀÇ ÁøÈ­
    • º» Á¶»çÀÇ ´ë»ó ¹üÀ§
  • Á¶»ç ´ë»ó³â
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¼¼°èÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå ¿ªÇÐ

  • ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀåÀÇ ¿µÇ⠺м®(2020-2030³â)
    • ½ÃÀå ÃËÁø¿äÀÎ
      • ¾ÏÀÇ Áõ°¡
      • ÀÇ·á ºÐ¾ß ÀÀ¿ëÀ» ÇâÇÑ Á¶»çÀÇ È°¹ßÈ­
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
      • ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ÀÇ °íºñ¿ë
    • ½ÃÀå ±âȸ
      • Á¦¾àȸ»çº° ¾à¹° °Ë»ç¿¡ ´ëÇÑ ÁöÃâ Áõ°¡
      • ±â¼úÀû Áøº¸ÀÇ Áõ°¡

Á¦4Àå ¼¼°èÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå »ê¾÷ ºÐ¼®

  • Porter's 5 Force ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • Porter's 5 Force ¿µÇ⠺м®
  • PEST ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦Àû
    • »çȸÀû
    • ±â¼úÀû
    • ȯ°æ
    • ¹ý·ü
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • COVID-19 ¿µÇ⠺м®
  • ÆÄ±«Àû µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ ½ÃÁ¡
  • ¾Ö³Î¸®½ºÆ®ÀÇ Á¦¾È°ú °á·Ð

Á¦5Àå ¼¼°èÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå : ÄÄÆ÷³ÍÆ®º°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå : ÄÄÆ÷³ÍÆ®º°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå, ÄÄÆ÷³ÍÆ®º° ÃßÁ¤¡¤¿¹Ãø 2020-2030
  • ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • Ãʺб¤ Ä«¸Þ¶ó
    • ¾×¼¼¼­¸®

Á¦6Àå ¼¼°èÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå, ¸ð´Þ¸®Æ¼º°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå : ¸ð´Þ¸®Æ¼º°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå, ¸ð´Þ¸®Æ¼º° ÃßÁ¤¡¤¿¹Ãø 2020-2030
  • ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • Ǫ½Ã ºê·ë
    • ½º³À¼ô
    • ±âŸ

Á¦7Àå ¼¼°èÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå : ¿ëµµº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå : ¿ëµµº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå, ¿ëµµº° ÃßÁ¤¡¤¿¹Ãø 2020-2030
  • ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • ǰÁú º¸Áõ°ú ¾à¹° °Ë»ç
    • ÀÇ·á¿ë Áø´Ü¾à
    • ±âŸ

Á¦8Àå ¼¼°èÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, ¼º´É - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ÃßÁ¤¡¤¿¹Ãø 2020-2030
  • ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • Á¦¾àȸ»ç, ¹ÙÀÌ¿ÀÀǾàǰ ȸ»ç
    • ¿¬±¸±â°ü¡¤´Üü
    • ±âŸ

Á¦9Àå ¼¼°èÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå : Áö¿ªº° ºÐ¼®

  • »óÀ§ÀÇ ÁÖ¿ä ±¹°¡
  • ÁÖ¿ä ½ÅÈï ±¹°¡
  • ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå, Áö¿ªº° ½ÃÀå ½º³À¼ô
  • ºÏ¹Ì
    • ¹Ì±¹
      • ÄÄÆ÷³ÍÆ® ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • ¸ð´Þ¸®Æ¼º° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • ¾ÖÇø®ÄÉÀÌ¼Ç ³»¿ª ÃßÁ¤°ú ¿¹Ãø, 2020-2030³â
      • ÃÖÁ¾»ç¿ëÀÚº° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
    • ij³ª´Ù
  • À¯·´ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå ½º³À¼ô
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå ½º³À¼ô
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÀÇ·á¿ë Ãʺб¤ À̹Ì¡ ½ÃÀå ½º³À¼ô
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
    • ±â¾÷ 1
    • ±â¾÷ 2
    • ±â¾÷ 3
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • Specim Private Limited
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫 Á¤º¸(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì¸¸)
      • Á¦Ç° °³¿ä
      • ÃÖ±Ù °³¹ß »óȲ
    • BaySpec, Inc.
    • Resonon Inc.
    • Headwall Photonics Inc
    • HyperMed Imaging, Inc.
    • XIMEA GmbH
    • Cubert Inc
    • Diaspective Vision gmbh
    • ClydeHSI Imaging and Technology Limited
    • Imec

Á¦11Àå Á¶»ç ÇÁ·Î¼¼½º

  • Á¶»ç ÇÁ·Î¼¼½º
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • ¹ë¸®µ¥À̼Ç
    • ÃâÆÇ
  • Á¶»çÀÇ Æ¯Â¡
  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç
KSA 23.06.12

Global Medical Hyperspectral Imaging Market is valued approximately USD 1.58 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 13.1% over the forecast period 2023-2030 Medical hyperspectral imaging is a specialized imaging technique used in the field of medicine to capture and analyze detailed information about the spectral properties of biological tissues. It combines principles of conventional imaging with spectroscopy to provide a wealth of information about the chemical and structural composition of tissues. The Medical Hyperspectral Imaging market is expanding because of factors such as increasing prevelance of cancer and increasing research to explore medical applications.

The rising prevalence of cancer globally is fostering market growth, according to estimates from the International Agency for Research on Cancer (IARC), The estimated increase in the worldwide burden of cancer is to 27.5 million new cases by 2040 from 1.9 million new cases in year 2021. Furthermore, Multiple studies' findings support the efficacy of hyperspectral imaging in cancer diagnosis. For instance, according to a research paper that appeared in Springer Nature in 2022, hyperspectral imaging may accurately diagnose breast cancer from breast tissue removed following surgery with a sensitivity of approximately 84%. Additionally, within a few minutes, medical hyperspectral imaging could analyse the tissue, allowing for the possibility of determining whether any tumour cells remained at the edges of the resection sites. One of the key reasons propelling the market expansion during the forecast period is the benefits and accuracy of this technology in the detection of cancer. In addition, rising expenditure on drug testing by pharmaceutical companies and rising technological advancements is creating a lucrative opportunity to the market. However, the high cost of Medical Hyperspectral Imaging stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Medical Hyperspectral Imaging Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to rising prevalence of cancer, rising research and development activities, and presence of key market players. Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising cancer prevelance, an increase in the number of collaborations for product development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market players included in this report are:

  • Specim Private Limited
  • BaySpec, Inc.
  • Resonon Inc.
  • Headwall Photonics Inc
  • HyperMed Imaging, Inc.
  • XIMEA GmbH
  • Cubert Inc
  • Diaspective Vision gmbh
  • ClydeHSI Imaging and Technology Limited
  • Imec

Recent Developments in the Market:

  • In July 2022, Headwall Photonics announced its plans for the acquisition of Holographix LLC. This acquisition would result in expanding the company manufacturing capabilities to address future growth.
  • In August 2022, the Europe government allocated roughly USD 27,711,189.54 to the research project HyPPOCRATES. By utilizing machine learning concepts, the research aims to develop a potent mHS image interpretation software platform for processing mHS data.

Global Medical Hyperspectral Imaging Market Report Scope:

  • Historical Data: - 2020 - 2021
  • Base Year for Estimation: - 2022
  • Forecast period: - 2023-2030
  • Report Coverage: - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: - Component, Modality, Application, End User Region
  • Regional Scope: - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Component offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Component:

  • Hyperspectral Cameras
  • Accessories

By Modality:

  • Push Broom
  • Snapshot
  • Others

By Application:

  • Quality Assurance & Drug Testing
  • Medical Diagnostics
  • Others

By End User:

  • Pharmaceutical & Biopharmaceutical Companies
  • Research Institutes & Organizations
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Medical Hyperspectral Imaging Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Medical Hyperspectral Imaging Market, by Component, 2020-2030 (USD Billion)
    • 1.2.3. Medical Hyperspectral Imaging Market, by Modality, 2020-2030 (USD Billion)
    • 1.2.4. Medical Hyperspectral Imaging Market, by Application, 2020-2030 (USD Billion)
    • 1.2.5. Medical Hyperspectral Imaging Market, by End User, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Medical Hyperspectral Imaging Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Medical Hyperspectral Imaging Market Dynamics

  • 3.1. Medical Hyperspectral Imaging Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing prevelance of cancer
      • 3.1.1.2. Increasing Research to Explore Medical Applications
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Medical Hyperspectral Imaging
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rising expenditure on drug testing by pharmaceutical companies
      • 3.1.3.2. Rising technological advancements

Chapter 4. Global Medical Hyperspectral Imaging Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Medical Hyperspectral Imaging Market, by Component

  • 5.1. Market Snapshot
  • 5.2. Global Medical Hyperspectral Imaging Market by Component, Performance - Potential Analysis
  • 5.3. Global Medical Hyperspectral Imaging Market Estimates & Forecasts by Component 2020-2030 (USD Billion)
  • 5.4. Medical Hyperspectral Imaging Market, Sub Segment Analysis
    • 5.4.1. Hyperspectral Cameras
    • 5.4.2. Accessories

Chapter 6. Global Medical Hyperspectral Imaging Market, by Modality

  • 6.1. Market Snapshot
  • 6.2. Global Medical Hyperspectral Imaging Market by Modality, Performance - Potential Analysis
  • 6.3. Global Medical Hyperspectral Imaging Market Estimates & Forecasts by Modality 2020-2030 (USD Billion)
  • 6.4. Medical Hyperspectral Imaging Market, Sub Segment Analysis
    • 6.4.1. Push Broom
    • 6.4.2. Snapshot
    • 6.4.3. Others

Chapter 7. Global Medical Hyperspectral Imaging Market, by Application

  • 7.1. Market Snapshot
  • 7.2. Global Medical Hyperspectral Imaging Market by Application, Performance - Potential Analysis
  • 7.3. Global Medical Hyperspectral Imaging Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
  • 7.4. Medical Hyperspectral Imaging Market, Sub Segment Analysis
    • 7.4.1. Quality Assurance & Drug Testing
    • 7.4.2. Medical Diagnostics
    • 7.4.3. Others

Chapter 8. Global Medical Hyperspectral Imaging Market, by End User

  • 8.1. Market Snapshot
  • 8.2. Global Medical Hyperspectral Imaging Market by End User, Performance - Potential Analysis
  • 8.3. Global Medical Hyperspectral Imaging Market Estimates & Forecasts by End User 2020-2030 (USD Billion)
  • 8.4. Medical Hyperspectral Imaging Market, Sub Segment Analysis
    • 8.4.1. Pharmaceutical & Biopharmaceutical Companies
    • 8.4.2. Research Institutes & Organizations
    • 8.4.3. Others

Chapter 9. Global Medical Hyperspectral Imaging Market, Regional Analysis

  • 9.1. Top Leading Countries
  • 9.2. Top Emerging Countries
  • 9.3. Medical Hyperspectral Imaging Market, Regional Market Snapshot
  • 9.4. North America Medical Hyperspectral Imaging Market
    • 9.4.1. U.S. Medical Hyperspectral Imaging Market
      • 9.4.1.1. Component breakdown estimates & forecasts, 2020-2030
      • 9.4.1.2. Modality breakdown estimates & forecasts, 2020-2030
      • 9.4.1.3. Application breakdown estimates & forecasts, 2020-2030
      • 9.4.1.4. End User breakdown estimates & forecasts, 2020-2030
    • 9.4.2. Canada Medical Hyperspectral Imaging Market
  • 9.5. Europe Medical Hyperspectral Imaging Market Snapshot
    • 9.5.1. U.K. Medical Hyperspectral Imaging Market
    • 9.5.2. Germany Medical Hyperspectral Imaging Market
    • 9.5.3. France Medical Hyperspectral Imaging Market
    • 9.5.4. Spain Medical Hyperspectral Imaging Market
    • 9.5.5. Italy Medical Hyperspectral Imaging Market
    • 9.5.6. Rest of Europe Medical Hyperspectral Imaging Market
  • 9.6. Asia-Pacific Medical Hyperspectral Imaging Market Snapshot
    • 9.6.1. China Medical Hyperspectral Imaging Market
    • 9.6.2. India Medical Hyperspectral Imaging Market
    • 9.6.3. Japan Medical Hyperspectral Imaging Market
    • 9.6.4. Australia Medical Hyperspectral Imaging Market
    • 9.6.5. South Korea Medical Hyperspectral Imaging Market
    • 9.6.6. Rest of Asia Pacific Medical Hyperspectral Imaging Market
  • 9.7. Latin America Medical Hyperspectral Imaging Market Snapshot
    • 9.7.1. Brazil Medical Hyperspectral Imaging Market
    • 9.7.2. Mexico Medical Hyperspectral Imaging Market
  • 9.8. Middle East & Africa Medical Hyperspectral Imaging Market
    • 9.8.1. Saudi Arabia Medical Hyperspectral Imaging Market
    • 9.8.2. South Africa Medical Hyperspectral Imaging Market
    • 9.8.3. Rest of Middle East & Africa Medical Hyperspectral Imaging Market

Chapter 10. Competitive Intelligence

  • 10.1. Key Company SWOT Analysis
    • 10.1.1. Company 1
    • 10.1.2. Company 2
    • 10.1.3. Company 3
  • 10.2. Top Market Strategies
  • 10.3. Company Profiles
    • 10.3.1. Specim Private Limited
      • 10.3.1.1. Key Information
      • 10.3.1.2. Overview
      • 10.3.1.3. Financial (Subject to Data Availability)
      • 10.3.1.4. Product Summary
      • 10.3.1.5. Recent Developments
    • 10.3.2. BaySpec, Inc.
    • 10.3.3. Resonon Inc.
    • 10.3.4. Headwall Photonics Inc
    • 10.3.5. HyperMed Imaging, Inc.
    • 10.3.6. XIMEA GmbH
    • 10.3.7. Cubert Inc
    • 10.3.8. Diaspective Vision gmbh
    • 10.3.9. ClydeHSI Imaging and Technology Limited
    • 10.3.10. Imec

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦